HC Wainwright reiterates Buy on Travere Therapeutics, $67 target
HC Wainwright & Co. reiterated a Buy rating on Travere Therapeutics (TVTX) with a $67.00 price target, implying 6.6% upside from the Sep 21 close of $62.86.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.